刘奕志

发布时间:2022-09-14 浏览:4750

中山大学中山眼科中心

刘奕志教授,国自然基金创新群体学术带头人、973计划首席科学家;中华医学会眼科分会副主任委员。实现了人类晶状体原位再生,开拓了用内源性干细胞治疗疾病的新方向,以通讯作者发表在Nature杂志,并被Nature Medicine杂志评为“2016年度全球医学八大突破性进展”。创新了多个白内障诊治技术:“扭动”模式白内障粉碎技术在全球广泛应用;曾在Science 、N Engl J Med 、Lancet 、BMJ 撰写临床述评和技术标准。研发出白内障1类新药化合物,已获多个国家的发明专利。曾获“何梁何利”科技进步奖、国家科技进步二等奖、全国“五一”劳动奖章等荣誉。



Dr. Yizhi Liu is Professor  of Zhongshan Ophthalmic Center, Chief of National 973 Programs. Dr. Liu is the Standing Committee of Asia-Pacific Academy of Ophthalmology Congress (APAO), Vice Chairman of Chinese Ophthalmological Society, Vice Leader of Cataract and Artificial Lens Group, Chinese Ophthalmological Society, Vice Chairman of Guangdong Medical Association, Chairman of Guangdong Ophthalmological Society. Dr. Liu also serves as co-Editor-in-Chief of the journal Molecular Vision, and Deputy Editor-in-Chief of Current Molecular Medicine.

Having been working in medical treatment, education, research of ophthalmology and blindness prevention for more than 30 years, he is one of the experts who carried out and promoted minimally invasive cataract surgeries in China. Currently, Dr. Liu is participating in several key research projects supported by National Key Research Plan, Key Program of National Natural Science Fund and Key International Cooperation Program of National Natural Science Fund etc.. He has authored more than 60 papers published in journals like NEJM, Nature, Science, BMJ, PNAS etc.. Dr. Liu received Arthur Lim Award of APAO in 2014.

返回列表
其他期刊
  • 眼科学报

    主管:中华人民共和国教育部
    主办:中山大学
    承办:中山大学中山眼科中心
    主编:林浩添
    主管:中华人民共和国教育部
    主办:中山大学
    浏览
  • Eye Science

    主管:中华人民共和国教育部
    主办:中山大学
    承办:中山大学中山眼科中心
    主编:林浩添
    主管:中华人民共和国教育部
    主办:中山大学
    浏览
推荐阅读
出版者信息